[widget id="nav_menu-11"][widget id="custom_html-3"]
Last updated: 6 April 2021
Start Time: 12:00 CEST / 06:00 EDT / 03:00 PDT
Duration: 1hour 40minutes
Presenations
- Involvement of the heart
- Brain Involvement in Myotonic Dystrophy Type 2
- When to investigate for neoplasia?
- Rhabdomyolysis
Time: 12:00 CEST / 06:00 EDT / 03:00 PDT
Duration: 1hour 40minutes
Presenations
- Approach to the Patient with Peripheral Neuropathy
- Differential Diagnosis and treatment of Acute Neuropathy
- Approach to the Patient with Hereditary Peripheral Neuro
- Diagnosis and Treatment of Diabetic Neuropathy
Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour 30minutes
Presenations
- Limb girde syndrome
- External ophthalmoplegia
- Bulbar Balsy
Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour 40minutes
Presenations
- Bulbar Weakness Inherited sensory and autonomic neuropathies: new clues on diagnosis and treatment
- Sensory Variants of Immune-Mediated Neuropathies; Clinical Challenges and Treatments
- Chemotherapy related sensory and painful neuropathies: strategies for prevention and treatment
- Small fibre neuropathy: from diagnosis to personalized treatments
Time: 16:00 CEST / 10:00 EDT / 07:00 PDT
Duration: 1hour 40minutes
Time: 12:00 CEST / 06:00 EDT / 03:00 PDT
Duration: 45 minutes
Start Time: 13:00 CEST / 07:00 EDT / 04:00 PDT
Duration: 1hour
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presenations
- FSHD: Setting the Stage
- FSHD: Genetics, Epigenetics and Genetic Diagnosi
- FSHD: Biomarkers, Outcome Measures and Therapies
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presenations
- Immune Myopathies: New syndromes
- Dermatomysitis
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
- Novel therapies in mitochondrial disorders
- Novel suggestions in treatment of muscle glycogenoses
- Emerging clinical entities in metabolic myopathies
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
- Visual representations of muscle MRI data
- Unravelling patterns of muscle involvement in distal myopathies
- Follow-up of muscle degeneration using quantitative muscle MRI
Start Time: 16:15 CEST / 10:15 EDT / 07:15 PDT
Duration: 1hour
- Non dystrophic myotonias
- Natural history and outcomes in DM1
- DM2 standard therapies
Start Time: 16:15 CEST / 10:15 EDT / 07:15 PDT
Duration: 1hour
- New genes causing distal myopathies
- Distal myopathy caused myosin and thin filament nebulin
- News on myofibrillar myopathies
Time: 17:15 CEST / 11:15 EDT / 08:15 PDT
Duration: 45 minutes
Time: 12:00 CEST / 06:00 EDT / 03:00 PDT
Duration: 45 minutes
Start Time: 13:00 CEST / 07:00 EDT / 06:00 PDT
Duration: 1hour
Presenations
- TRR Amyloidosis
- SMA
- CMT: new treatment concepts and pathways
Start Time: 13:00 CEST / 07:00 EDT / 06:00 PDT
Duration: 1hour
Presenations
- Overview on Paraneoplastic Neuropathies
- Paraneoplastic Sensory Neuronopathy
- Paraneoplastic Neuromytonia
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presentations:
- EAN/PNS guideline on diagnosis and management of Guillain-Barré syndrome
- Acute and chronic inflammatory neuropathies and COVID-1
- EAN/PNS guideline on diagnosis and management of chronic inflammatory demyelinating polyradiculoneuropathy - Second revision
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presentations:
- From nerve to roots
- When to do and how to do
- Pathology of the nodal complex in CIDP
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- CMT Approach to diagnosis
- Autosomal recessive CMT
- Early diagnosis of hATTR neuropathy
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- Clinical indications and normative reference values
- Clues on degeneration and regeneration of somatic and autonomic nerves
Time: 16:15 CEST / 10:15 EDT / 07:15 PDT
Duration: 45 minutes
Time: 12:00 CEST / 06:00 EDT / 03:00 PDT
Duration: 45 minutes
Start Time: 13:00 CEST / 07:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- Early onset and Juvenile Myasthenia Gravis
- Ocular Myasthenia Gravis
- Myasthenia Gravis in seniors
Start Time: 13:00 CEST / 07:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- Progression of DMD and link between progression and critical milestones, effect of corticosteroids
- Dystrophin quantification in diagnostic pathology and clinical trials: implication for diagnosis and translational research
- The role of gene modifiers in DMD
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presentations:
- Immunoactive drug therapy
- Antisense, RNA silence and other potentials gene therapies in MG
- Physical training and exercise as treatment for MG
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presentations:
- Triadopathies
- Sarcomeropathies
- Congenital Myopathies Across the Ages
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- LRP4-antibodies
- MuSK antibodies
- Maternal antibodies – long-term and short-term effects
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- CMS related to glycosylation disorders
- Extracellular matrix in myasthenic syndromes
- Mitochondrial pathology in myasthenic syndromes
Time: 16:15 CEST / 10:15 EDT / 07:15 PDT
Duration: 45 minutes
Time: 12:00 CEST / 06:00 EDT / 03:00 PDT
Duration: 45 minutes
Start Time: 13:00 CEST / 07:00 EDT / 06:00 PDT
Duration: 1hour
Presenations
- Advances in the clinical diagnosis and biomarkers in ALS. Are they ready for clinical trials?
- Clinical Trials in ALS
- Antisense & SiRNA Therapies
Start Time: 13:00 CEST / 07:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- Neurophysiology
- Imaging
- CSF Markers
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presentations:
- Cognitive and Behavioural Impairment in ALS
- Motor Symptoms and Signs in FTD
- Genetic and Pathologic Overlap
Start Time: 14:00 CEST / 08:00 EDT / 05:00 PDT
Duration: 1hour
Presentations:
- Tubulinopathies as neurodegenerative disease
- Developing treatment for SMARD1
- Developing treatment for Brown-Vialetto-Van Laere Syndrome
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- Natural history of SMA
- SMA registries: what, when and how to register?
- New treatments in adult SMA: evidences from the clinical practice
Start Time: 15:00 CEST / 09:00 EDT / 06:00 PDT
Duration: 1hour
Presentations:
- Multidisciplinary approach of ALS
- Technology to improve technical care and trials in MND
- Palliative care
Start Time: 16:15 CEST / 10:15 EDT / 07:15 PDT
Duration: 1hour
Time: 17:15 CEST / 11:15 EDT / 08:15 PDT
Duration: 45 minutes
CME Information
The ICNMD 2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 17 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA
Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Credits will be awarded for ICNMD 2021 sessions viewed live through May 29, 2021. Each participant can only receive the number of credits they are entitled to according to their
actual participation after completing the evaluation form. Evaluation forms must be submitted within two weeks on Congress.
The ICNMD2021 virtual library access will expire on 5 April 2022.